GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older

Phase 2

Completed

Conditions: Influenza, Human

Interventions: Biological: FLU-Q-PAN H7N9 Formulation 1
Biological: FLU-Q-PAN H7N9 Formulation 2
Biological: FLU-Q-PAN H7N9 Formulation 3
Drug: Placebo
Biological: AS03A
Biological: AS03B

First Posted Date: 2021-03-09

Last Posted Date: 2023-10-10

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 833

Registration Number: NCT04789577

Locations: 🇺🇸
GSK Investigational Site, West Jordan, Utah, United States

Molecular Disease Characterization Initiative (MDCI)

Phase 2

Terminated

Conditions: Lung Cancer, Non-Small Cell
Neoplasms

Interventions: Procedure: Tumor biopsy

First Posted Date: 2021-02-26

Last Posted Date: 2024-04-19

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 6

Registration Number: NCT04772053

Locations: 🇪🇸
GSK Investigational Site, Madrid, Spain

A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years

Phase 1

Terminated

Conditions: Herpes Simplex

Interventions: Drug: Placebo (saline)
Biological: Low dose formulation of HSV vaccine (GSK4108771A)
Biological: Medium dose formulation of HSV vaccine (GSK4108771A)
Biological: High dose formulation of HSV vaccine (GSK4108771A)
Biological: Lower dose formulation of HSV vaccine (GSK4108771A)

First Posted Date: 2021-02-21

Last Posted Date: 2021-06-28

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 17

Registration Number: NCT04762511

Locations: 🇺🇸
GSK Investigational Site, Rochester, New York, United States

A Study of the Safety of and Immune Response to Varying Doses of a Vaccine Against COVID-19 in Healthy Adults

Phase 1

Completed

Conditions: Virus Diseases

Interventions: Biological: 1 µg CoV2 SAM (LNP)

First Posted Date: 2021-02-17

Last Posted Date: 2024-01-18

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 40

Registration Number: NCT04758962

Locations: 🇺🇸
GSK Investigational Site, Rochester, New York, United States

Sun Protection Factor (SPF) Determination of Two Sunscreen-Containing Lip Balms

Not Applicable

Completed

Conditions: Sunscreening Agents

Interventions: Drug: ChapStick Moisturizer, Classic Flavor
Drug: ChapStick Moisturizer, Strawberry Flavor

First Posted Date: 2021-02-11

Last Posted Date: 2022-03-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 14

Registration Number: NCT04749459

Locations: 🇺🇸
GSK Investigational Site, Fairfield, New Jersey, United States

A Proof-of-principle Clinical Study Investigating the Efficacy of an Experimental Dentifrice Containing Sodium Bicarbonate and Sodium Hyaluronate on Gingivitis

Phase 2

Completed

Conditions: Gingivitis

Interventions: Other: Positive control dentifrice
Other: Negative control dentifrice
Other: Experimental Dentrifrice

First Posted Date: 2021-02-04

Last Posted Date: 2024-01-19

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 110

Registration Number: NCT04737538

Locations: 🇨🇦
GSK Investigational Site, Mississauga, Ontario, Canada

Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above

Phase 3

Active, not recruiting

Conditions: Respiratory Syncytial Virus Infections

Interventions: Biological: RSVPreF3 OA investigational vaccine

First Posted Date: 2021-02-01

Last Posted Date: 2023-12-21

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1720

Registration Number: NCT04732871

Locations: 🇨🇳
GSK Investigational Site, Taoyuan County, Taiwan

A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

Phase 3

Recruiting

Conditions: Asthma

Interventions: Biological: GSK3511294 (Depemokimab)
Biological: Mepolizumab
Biological: Benralizumab
Biological: Placebo
Drug: Standard of care (SoC)
Device: Pre-filled Syringes (PFS)

First Posted Date: 2021-01-22

Last Posted Date: 2024-04-30

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1700

Registration Number: NCT04718389

Locations: 🇬🇧
GSK Investigational Site, Wishaw, United Kingdom

A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

Phase 3

Completed

Conditions: Asthma

Interventions: Biological: GSK3511294
Biological: Placebo

First Posted Date: 2021-01-22

Last Posted Date: 2024-11-28

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 397

Registration Number: NCT04718103

Locations: 🇨🇳
GSK Investigational Site, Taipei, Taiwan

Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

Phase 3

Completed

Conditions: Asthma

Interventions: Biological: GSK3511294 (Depemokimab)
Drug: Placebo

First Posted Date: 2021-01-22

Last Posted Date: 2024-12-17

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 395

Registration Number: NCT04719832

Locations: 🇬🇧
GSK Investigational Site, Nottingham, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy